Market Currents
Buy the recent weakness in Endo Pharmaceuticals (ENDP +0.5%) sparked by yesterday's FDA's denial...
-
Wednesday, April 11, 2012, 3:20 PM ETBuy the recent weakness in Endo Pharmaceuticals (ENDP +0.5%) sparked by yesterday's FDA's denial of ViroPharma's Vancocin citizen petition, Cantor Fitzgerald says. The firm notes heightened investor anxiety around approval of ENDP's generic Liboderm amid the VPHM news, but it believes "Vancocin is not a good proxy for Liboderm." (also)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
